Core Viewpoint - The company has completed the repurchase and cancellation of a portion of restricted stock, which does not lead to an adjustment in the conversion price of its convertible bonds. Group 1: Convertible Bonds Information - The company issued 6.9 million convertible bonds with a total value of 69 million yuan, approved by the China Securities Regulatory Commission on July 6, 2023 [1] - The bonds began trading on the Shanghai Stock Exchange on August 2, 2023, under the name "东亚转债" and code "111015" [2] - The initial conversion price was set at 24.95 yuan per share, which is currently adjusted to 20.28 yuan per share [2] Group 2: Stock Repurchase and Cancellation - The company plans to repurchase and cancel 14,000 shares of restricted stock due to the departure of one incentive recipient [2][3] - The cancellation is expected to be completed by August 27, 2025 [3] Group 3: Conversion Price Adjustment - The conversion price of "东亚转债" will not change as the repurchased restricted stock represents a small proportion of the total share capital [5] - The adjustment formula for the conversion price is outlined in the prospectus, which includes various scenarios such as stock dividends and capital increases [4] - The calculated conversion price remains at approximately 20.28 yuan per share after applying the adjustment formula [5]

Core Viewpoint - East Asia Pharmaceutical plans to repurchase and cancel 14,000 restricted stocks due to one incentive object voluntarily resigning, with the cancellation expected to be completed by August 27, 2025 [1][2]. Group 1: Repurchase and Cancellation Decision - On June 30, 2025, East Asia Pharmaceutical held its fourth board meeting and eighth supervisory board meeting, where the proposal for repurchasing and canceling part of the restricted stocks was approved [2]. - The repurchase involves one incentive object who no longer qualifies for the restricted stock incentive due to voluntary resignation, and the company will repurchase the stocks at the grant price [2]. - The company has opened a dedicated securities account for the repurchase and applied for the cancellation procedures with the China Securities Depository and Clearing Corporation [2]. Group 2: Changes in Share Structure - After the repurchase and cancellation, the number of restricted circulating shares will decrease from 2,156,103 shares to 2,142,103 shares [3]. - The final share structure change will be confirmed by the China Securities Depository and Clearing Corporation after the cancellation is completed [3]. Group 3: Compliance and Legal Opinions - The board of directors stated that the decision-making process and information disclosure for the repurchase and cancellation are compliant and do not harm the interests of the incentive object or creditors [4]. - The company has committed to the accuracy and completeness of the information and has informed the incentive object without objection [4]. - Shanghai Junlan Law Firm believes that the repurchase and cancellation have obtained necessary approvals and are in compliance with relevant regulations, with minimal impact on the company's finances and operations [4].

证券代码：605177 证券简称：东亚药业 公告编号：2025-041 经中国证券监督管理委员会证监许可〔2023〕1165 号文核准，公司于 2023 年 7 月 6 日发行了 690 万张可转换公司债券，每张面值 100 元，发行总额 69,000 万元，期限 6 年。 经上海证券交易所（以下简称"上交所"）自律监管决定书〔2023〕166 号文 同意，公司发行的 69,000 万元可转换公司债券于 2023 年 8 月 2 日起在上交所挂 牌交易，债券简称"东亚转债"，债券代码"111015"。 债券代码：111015 债券简称：东亚转债 浙江东亚药业股份有限公司 关于部分限制性股票回购注销完成 不调整可转债转股价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 因本次回购注销的限制性股票占浙江东亚药业股份有限公司（以下简称 "公司"）总股本比例较小，经计算并四舍五入，本次限制性股票回购注销完成后， "东亚转债"转股价格不变。 一、可转换公司债券基本情况 根据有关规定和《浙江东亚药业股份有限公 ...

重要内容提示： ● 回购注销原因：浙江东亚药业股份有限公司（以下简称"公司"）根据《上 市公司股权激励管理办法》（以下简称"《管理办法》"）、《浙江东亚药业股 份有限公司 2024 年限制性股票激励计划》（以下简称"《激励计划》"或"本激励 计划"），鉴于本激励计划授予的 1 名激励对象主动辞职，本次拟回购注销上述 激励对象已获授但尚未解除限售的限制性股票合计 14,000 股。 ● 本次注销股份的有关情况 | | | 浙江东亚药业股份有限公司 关于股权激励部分限制性股票回购注销实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 回购股份数量 | 注销股份数量 | | 注销日期 | | | | | --- | --- | --- | --- | --- | --- | --- | | 股 14,000 | 14,000 | 股 | 8 | 年 2025 | 月 | 日 27 | 一、本次限制性股票回购注销的决策与信息披露 2025 年 6 月 30 日，公司召开第四届董事会第九次会议和第四届监事会第八 次会议，分别审 ...

之 法律意见书 2024 年限制性股票激励计划 回购注销部分限制性股票实施相关事项 上海君澜律师事务所 关于 浙江东亚药业股份有限公司 关于浙江东亚药业股份有限公司 2024 年限制性股票激励计划 二〇二五年八月 回购注销部分限制性股票实施相关事项之 法律意见书 致：浙江东亚药业股份有限公司 上海君澜律师事务所（以下简称"本所"）接受浙江东亚药业股份有限公司（以 下简称"公司"或"东亚药业"）的委托，根据《中华人民共和国公司法》（以下简 称"《公司法》"）、《浙江东亚药业股份有限公司 2024 年限制性股票激励计划》 （以下简称"《激励计划》"或"本次激励计划"）的规定，就东亚药业回购注销本 次激励计划 1 名激励对象已获授但尚未解除限售的限制性股票（以下简称"本次回购 注销"）实施相关事项出具本法律意见书。 对本法律意见书，本所律师声明如下： （一）本所律师依据《中华人民共和国证券法》《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定及本法律意见书 出具日以前已经发生或者存在的事实，严格履行了法定职责，遵循了勤勉尽责和诚实 信用原则，进行了充分的核查验证，保证本法律意 ...

证券时报·数据宝统计，截至发稿，东亚药业收盘价为20.59元，下跌1.01%，本期筹码集中以来股价累 计下跌0.96%。具体到各交易日，6次上涨，6次下跌。 （文章来源：证券时报网） 公司发布的一季报数据显示，一季度公司共实现营业收入1.91亿元，同比下降45.85%，实现净利 润-691.96万元，同比下降128.78%，基本每股收益为-0.0600元。 东亚药业8月18日披露，截至8月10日公司股东户数为11274户，较上期（7月31日）减少629户，环比降 幅为5.28%。 7月15日公司发布上半年业绩预告，预计实现净利润-3500.00万元至-2800.00万元，变动区间 为-207.78%~-186.23%。（数据宝） ...

Core Insights - The report highlights the significant role of company secretaries (董秘) as a bridge between investors and listed companies, emphasizing their importance in capital operations within the A-share market [1] Salary Overview - The total salary for A-share company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - In the raw material pharmaceutical sector, the average annual salary for company secretaries is 608,400 yuan [1] Demographics - The age distribution shows that 60% of company secretaries are between 30-50 years old, while 38% are over 50, and only 2% are 30 or younger [1] - Educational background indicates that over 50% of company secretaries hold a bachelor's degree, with 9% having an associate degree, 39% holding a master's degree [1] Salary Distribution in Raw Material Pharmaceutical Sector - Among company secretaries in the raw material pharmaceutical sector, 49% earn below 500,000 yuan, 40% earn between 500,000 and 1 million yuan, and 11% earn over 1 million yuan [1] Top Earners - The top five highest-paid company secretaries are from Guobang Pharmaceutical, Saifen Technology, Keyuan Pharmaceutical, Aorite, and Zhejiang Pharmaceutical, with salaries ranging from 1.0832 million to 1.9309 million yuan [2] - The lowest-paid company secretaries earn below 200,000 yuan, with their salaries ranging from 174,200 to 190,700 yuan [2]

Core Insights - The report highlights that in 2024, the total salary for A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 708,000 yuan [1] - A total of 1,144 company secretaries earned over 1 million yuan, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary for company secretaries in the A-share raw material pharmaceutical sector is 608,400 yuan [2] - The distribution of salaries shows that 49% earn below 500,000 yuan, 40% earn between 500,000 and 1 million yuan, and 11% earn above 1 million yuan [2] - The top five highest-paid company secretaries have annual salaries of 1.9309 million yuan, 1.514 million yuan, 1.2 million yuan, 1.17 million yuan, and 1.1 million yuan respectively [2] Age and Education Distribution - Company secretaries aged between 30 and 50 constitute 60% of the market, while those over 50 account for 38%, and those aged 30 or below make up 2% [1] - More than half of the company secretaries hold a bachelor's degree, with 9% having an associate degree, 52% a bachelor's degree, and 39% a master's degree [1] Investor Engagement - There is significant variation in the number of investor meetings held by companies, with 43% of companies hosting fewer than 10 meetings annually [2] - The top five companies with the most investor meetings conducted 520, 437, 325, 323, and 291 meetings respectively [3]

Core Insights - The report highlights that in 2024, the total salary for A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - Over 21% of company secretaries earn more than 1 million yuan annually, indicating a significant portion of high earners in this role [1] Salary Distribution - The average annual salary for secretaries in the A-share pharmaceutical sector is 608,400 yuan [5] - The distribution of salaries shows that 49% earn below 500,000 yuan, 40% earn between 500,000 and 1 million yuan, and 11% earn above 1 million yuan [5] - The top five highest-paid secretaries have salaries ranging from 1.0832 million to 1.9309 million yuan, with varying years of service [7] Age and Education Demographics - The majority of company secretaries (60%) are aged between 30 and 50 years, while 38% are over 50 years, and only 2% are 30 years or younger [1] - More than half (52%) of the secretaries hold a bachelor's degree, with 39% holding a master's degree and 9% holding an associate degree [3] Investor Relations - There is a significant variance in the number of investor meetings held by companies, with 43% of companies hosting fewer than 10 meetings annually [9] - The five companies with the highest number of investor meetings range from 291 to 520 meetings per year, with their secretaries' salaries varying widely [9]

Core Insights - The report highlights that in 2024, the total salary of A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 company secretaries earned over 1 million yuan, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary for company secretaries in the A-share raw material pharmaceutical sector is 608,400 yuan [5] - The distribution of salaries shows that 49% earn below 500,000 yuan, 40% earn between 500,000 and 1 million yuan, and 11% earn above 1 million yuan [5] Age and Education Distribution - Company secretaries aged between 30 and 50 constitute 60% of the market, while those over 50 account for 38%, and those aged 30 or below make up 2% [3] - Over half of the company secretaries hold a bachelor's degree, with the breakdown being 9% with an associate degree, 52% with a bachelor's degree, and 39% with a master's degree [3] Top and Bottom Salaries - The top five highest-paid company secretaries have annual salaries of 1.9309 million yuan, 1.514 million yuan, 1.2 million yuan, 1.176 million yuan, and 1.0832 million yuan, respectively [7] - The three lowest-paid company secretaries earn 174,200 yuan, 187,500 yuan, and 190,700 yuan, all of whom have served in their positions for less than two years [7] Investor Engagement - There is significant variation in the number of investor meetings held by companies, with 43% of companies hosting fewer than 10 meetings annually [9] - Five companies reported zero investor meetings, while the top five companies for investor engagement had between 291 and 520 meetings, with corresponding secretary salaries ranging from 267,000 yuan to 444,200 yuan [9]